Table 2: CYP2C19 inhibitors.

Weak	Moderate*	Strong*	Class not well defined
Allicin Armodafinil Carbamazepine Cimetidine Desipramine Etravirine Ethinylestradiol Felbamate Fenofibrate Ketoconazole Nortriptyline Oral contraceptives† Topiramate	Eslicarbazepine Esomeprazole Fluoxetine Moclobemide Omeprazole Voriconazole	Amitriptyline Clomipramine Fluconazole Fluvoxamine Imipramine Ticlopidine	Cannabidiol Cenobamate Lansoprazole Oxcarbazepine Telmisartan Vilazodone

Concomitant use of mavacamten with CYP2C19 inhibitors can inhibit mavacamten metabolism, and it may increase the risk of adverse drug reactions and may require dose adjustments.

^*Concomitant use of mavacamten with moderate or strong CYP2C19 inhibitors increase blood drug levels and may increase the risk of heart failure due to systolic dysfunction and are therefore contraindicated. ^† Mavacamten may reduce the effectiveness of combined hormonal contraception drugs. The patients should be advised to use the appropriate contraception methods.